{"id":"W2413316483","doi":"10.1093/ajhp/59.10.941","title":"Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia","year":2002,"lang":"en","type":"article","venue":"American Journal of Health-System Pharmacy","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Chemotherapy; Internal medicine; Cytarabine; Mitoxantrone; Calicheamicin; Surgery; Myeloid leukemia; CD33","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005268646,0.0001789723,0.0005456622,0.0004593565,0.000431517,0.0004965009,0.000166615,0.0003888699,0.0004279916],"category_scores_gemma":[0.002209505,0.0001281241,0.0004518285,0.0005079461,0.0002803777,0.0003657057,0.000407495,0.0004570216,0.00008775285],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000577174,"about_ca_system_score_gemma":0.0002462521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001017406,"about_ca_topic_score_gemma":0.001795054,"domain_scores_codex":[0.9995704,0.0001548284,0.00004971006,0.00005243308,0.00006688829,0.0001058096],"domain_scores_gemma":[0.9989786,0.0001715665,0.0004492213,0.00003579498,0.00006814689,0.0002966813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004708792,0.0003784256,0.9832304,0.00002302465,0.0002153134,0.0007528658,0.0001768358,0.0002352162,0.0009257807,0.00003923243,0.0001891351,0.009124923],"study_design_scores_gemma":[0.0003633115,0.004986495,0.9913077,0.00001514336,0.0001429791,0.001452629,0.0002397634,0.0006815252,0.0003046618,0.00009070629,0.0003993796,0.00001570459],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9995925,0.0002126002,0.00002407997,0.00003598412,0.000005402234,0.000005606763,0.00002846795,0.000001101594,0.00009433034],"genre_scores_gemma":[0.9996277,0.00008733645,0.00002881421,0.00004128634,0.00002023952,0.000008267229,0.0001454637,7.968479e-7,0.00004018014],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001017406,"threshold_uncertainty_score":0.004187644,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02757580737803302,"score_gpt":0.328183563977453,"score_spread":0.30060775659942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}